Overview

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
First-line tocilizumab treatment during 6 months could permit rapid steroid-tapering and induction of remission in Takayasu arteritis (TA).
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Chugai Pharmaceutical